Showing 5651-5660 of 9115 results for "".
- Physician Assistant Groups Respond to JAMA Dermatology Study: "Fundamentally Flawed"https://practicaldermatology.com/news/physician-assistant-groups-respond-to-jama-dermatology-study-fundamentally-flawed/2457798/The American Academy of PAs (AAPA) and the Society of Dermatology PAs (SDPA) have issued a statemen
- Study: Derms More Likely than PAs to Catch Early Skin Cancerhttps://practicaldermatology.com/news/study-derms-more-likely-than-pas-to-catch-early-skin-cancer/2457800/Physician assistants may be more likely than dermatologists to perform unnecessary skin biopsies to check for cancer and are less likely to accurately diagnose early stage skin cancers, according to new research conducted by the University of Pittsbur
- Cutera: 20 Years, 20 Productshttps://practicaldermatology.com/news/cutera-20-years-20-products/2457802/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20
- Dermatologist Publishes Practice Planning Guide, "Moxie Mindset"https://practicaldermatology.com/news/dermatologist-publishes-practice-planning-guide-moxie-mindset/2457804/New York City dermatologist Dina D. Strachan, MD has published "Moxie Mindset," a book that offers "secrets of building a profitable, independent physicians practice in a competitive environment." Dr. Strachan details her personal journey to building a thriv
- News You Can Use: Simple One-Page Tool Improves Patient Satisfaction with Doctor Visithttps://practicaldermatology.com/news/news-you-can-use-simple-one-page-tool-improves-patient-satisfaction-with-doctor-visit/2457805/A simple, one-page form given to patients ahead of time can significantly improve satisfaction with care, according to a study by Duke Health researchers. The low-tech tool, which asks for a list of the topics patients wants to discuss during their visit, helps patients focus on what&rsqu
- Using Anti-PD-1 Therapy Pre-Surgery in Melanoma Patients Can Identify Those Most Likely to Benefithttps://practicaldermatology.com/news/using-anti-pd-1-therapy-pre-surgery-in-melanoma-patients-can-identify-those-most-likely-to-benefit/2457806/Shifting use of anti-PD-1 drugs to before surgery may provide clues about which patients will benefit and which may be at increased risk for recurrence, according to new research out of the Abramson Cancer Center of the University of Pennsylvania.
- New JAMA Dermatology Publication Features AID Accelerator Fund to Enable Progress of Promising Early-stage Scientific Technologieshttps://practicaldermatology.com/news/new-jama-dermatology-publication-features-aid-accelerator-fund-to-enable-progress-of-promisingearly-stage-scientific-technologies/2457810/A new article, "Catalyzing Future Drug, Device, and Information Technology Breakthroughs in Dermatology", in JAMA Dermatology features the Advancing Innovation in Dermatology (AID) Accelerator Fund. AID has created this mechanism to help enable and speed the product development
- Ortho Dermatologics' DUOBRII Improves Psoriasis Symptoms As Early As Two Weekshttps://practicaldermatology.com/news/ortho-dermatologics-duobrii-improves-psoriasis-symptoms/2457811/DUOBRII (halobetasol propionate and tazarotene) (IDP-118) lotion demonstrated significant superiority over vehicle as early as two weeks, according to new research in Journal of the American Academy of Dermatology</
- Aclaris Partners with Cipher to Seek Approval and Commercialize A-101 40% for Seborrheic Keratoses in Canadahttps://practicaldermatology.com/news/aclaris-partners-with-cipher-to-seek-approval-and-commercialize-a-101-40-for-seborrheic-keratoses-in-canada/2457814/Aclaris Therapeutics, Inc., has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101 40%) to Cipher Pharmaceuticals. A-101 40% was FDA approved in December 2017 and is marketed by Aclaris in the U.S. under the tradename E
- FDA Approves Sonoma Pharmaceuticals' Antimicrobial Post-Therapy Gelhttps://practicaldermatology.com/news/fda-approves-sonoma-pharmaceuticals-antimicrobial-post-therapy-gel/2457813/Sonoma Pharmaceuticals, Inc. has received a new 510(k) clearance from the FDA for an antimicrobial post-therapy gel. Under the supervision of a healthcare professional, the new product is intended for the management of post-non-ablative laser therapy procedures and post-microdermabrasion therapy